Viewing Study NCT01851551

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:40 PM
Ignite Modification Date: 2026-02-12 @ 7:34 PM
Study NCT ID: NCT01851551
Status: COMPLETED
Last Update Posted: 2020-01-03
First Post: 2013-04-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Sponsor: Acrotech Biopharma Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Hodgkin's Lymphoma View
None Diffuse Large B-cell Lymphoma View
None Mantle Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NHL View
None non-Hodgkin's lymphoma View
None diffuse large b-cell lymphoma View
None mantle cell lymphoma View